共 215 条
[1]
Sakai F(2016)Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 17 954-976
[2]
Igarashi H(1997)Prevalence of migraine in Japan: a nationwide survey Cephalalgia 17 15-22
[3]
Sakai F(2021)Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients Headache 61 1102-1111
[4]
Suzuki N(2021)Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study Headache 61 927-935
[5]
Kim BK(2018)Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial Cephalalgia 38 1442-1454
[6]
Tatsuoka Y(2017)A Controlled Trial of Erenumab for Episodic Migraine N Engl J Med 377 2123-2132
[7]
Imai N(2018)Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial JAMA 319 1999-2008
[8]
Ning X(2022)Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial Cephalalgia 42 108-118
[9]
Ishida M(2022)Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis BMC Neurol 22 512-1217
[10]
Nagano K(2021)Predictors of response to erenumab after 12 months of treatment Brain Behav 11 e2260-1208